logo

For the Inventor, By the Inventor

Wädenswil, Switzerland

Numab Therapeutics Ag


USPTO Granted Patents = 15



Trademarks = 2

Forward Citations = 5

Loading Chart...
Loading Chart...

15 inventors (with patents filed for the assignee):

goldMedal Sebastian Meyer (11 out of 18 patents)

silverMedal Tea Gunde (10 out of 27 patents)

bronzeMedal Christian Hess (10 out of 11 patents)

4.  David M Urech (10 out of 50 patents)

5.  Alexandre Simonin (7 out of 8 patents)

6.  Stefan Warmuth (4 out of 4 patents)

7.  Matthias Brock (3 out of 4 patents)

8.  Tessa Bieri (1 out of 1 patent)

9.  Teddy Beltrametti (1 out of 1 patent)

10.  Dania Diem (1 out of 1 patent)

11.  Maria Johansson (1 out of 1 patent)

12.  Julia Tietz (1 out of 1 patent)

13.  Noriko Shiraishi (1 out of 1 patent)

14.  Yoshio Arakawa (1 out of 1 patent)

15.  Yoshihide Miyake (1 out of 1 patent)


15 patents:

1. 12723101 - ANTIBODY SPECIFICALLY BINDING TO HUMAN SERUM ALBUMIN (2026-09-01),
2. 12703752 - MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR IL-4R AND IL-31, ENCODING NUCLEIC ACIDS THEREOF AND METHODS OF TREATING (2026-08-11),
3. 12503505 - MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR TNFA AND IL-17A, ANTIBODIES TARGETING IL-17A, AND METHODS OF USE THEREOF (2025-12-23),
4. 12209133 - Antibodies targeting CD137 and methods of use thereof (2025-01-28),
5. 12202911 - Multispecific antibody comprising CD137 binding domain and PDL1 binding domain (2025-01-21),
6. 12098203 - Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA (2024-09-24),
7. 12077588 - Antibodies targeting PDL1 and methods of use thereof (2024-09-03),
8. 11879005 - Hetero-dimeric multi-specific antibody format (2024-01-23),
9. 11427628 - Antibody frameworks (2022-08-30),
10. 11421035 - Stable antibody variable domain framework combinations and methods of use thereof (2022-08-23),
11. 11365240 - Anti-HSA antibodies (2022-06-21),
12. 11319371 - Anti-CD3 antibodies (2022-05-03),
13. 11236150 - Hetero-dimeric multi-specific antibody format (2022-02-01),
14. 10774140 - Anti-TNFα-antibodies and functional fragments thereof (2020-09-15),
15. 10077312 - CD3 and IL-23 receptor binding bispecific constructs and their use in the treatment of various diseases (2018-09-18),
Company Overview
Numab Therapeutics AG, based in Wädenswil, Switzerland, is a biopharmaceutical company focused on the development of innovative therapeutic solutions. The company specializes in the design and engineering of multi-specific antibodies and other biologics aimed at treating various diseases, including cancer and autoimmune disorders. Numab leverages its proprietary technology platforms to create differentiated therapies that address unmet medical needs, emphasizing a commitment to advancing healthcare through scientific excellence.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

15 Patents

#1 in Wädenswil

#804 in Switzerland

#39,881 in the World

Wädenswil, CH
Wädenswil, Switzerland

Numab Therapeutics Ag

Forward Citations = 5

15 inventors:

goldMedal Sebastian Meyer (11 out of 18 patents)

silverMedal Tea Gunde (10 out of 27 patents)

bronzeMedal Christian Hess (10 out of 11 patents)

4.  David M Urech (10 out of 50 patents)

5.  Alexandre Simonin (7 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Numab Therapeutics Ag. Retrieved from https://idiyas.com/company/numab-therapeutics-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…